Artivion, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AORT research report →
Range $30 – $45
Price Chart
About the company
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications.
- CEO
- James Patrick Mackin
- IPO
- 1993
- Employees
- 1,800
- HQ
- Kennesaw, GA, US
Get TickerSpark's AI analysis on AORT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $886.02M
- P/E
- -50.81
- Fwd P/E
- 129.71
- PEG
- -0.22
- P/S
- 1.85
- P/B
- 1.99
- EV/EBITDA
- 29.68
- Div Yield
- 0.00%
- Gross Margin
- 61.78%
- Op Margin
- 1.92%
- Net Margin
- -3.65%
- ROE
- -3.93%
- ROIC
- 0.95%
Latest fiscal year · YoY change
- Revenue
- $441.33M+13.6%
- Gross Profit
- $270.45M+8.7%
- Op Income
- $26.75M
- Net Income
- $9.77M+173.1%
- EPS
- $0.22+168.8%
- OCF Growth
- +79.3%
- FCF Growth
- -92.4%
- 52W High
- $48.25
- 52W Low
- $18.11
- 50D MA
- $22.35
- 200D MA
- $27.90
- Beta
- 1.28
- RSI (14)
- 33
- Avg Volume
- 669.51K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Artivion posted 9% constant-currency revenue growth in Q3, but profitability fell as launch and manufacturing investments weighed on margins while management reiterated confidence in AMDS, On-X, and the upcoming NEXUS launch.· November 5, 2026
- Total revenue was $123.8 million, up 9% year over year on a constant-currency basis; adjusted EBITDA fell 8% to $22.5 million and margin declined to 18.2%.
- Stent graft revenue grew 12% and On-X grew 13%, while tissue processing was roughly flat and BioGlue was modestly higher.
- Management said AMDS implant volumes are improving, but U.S. starter-set sales remain constrained by hospital administrative hurdles around the upfront $100,000 purchase.
- NEXUS launch preparation is on track for January 2027, with inventory build, sales hiring, and surgeon training underway.
- Full-year 2026 guidance was narrowed to 8% to 10% adjusted constant-currency growth, $484 million to $492 million of reported revenue, and $93 million to $98 million of adjusted EBITDA.
Q3 2026 revenue was $123.8 million, up 9% year over year on a constant-currency basis; excluding PerClot, growth was 8%. Adjusted EBITDA was $22.5 million versus $24.6 million a year ago, down about 8%, and adjusted EBITDA margin was 18.2%, down about 350 basis points. Gross margin was 61.4% versus 65.6% last year. By product line, stent graft revenue increased 12%, On-X increased 13%, tissue processing declined 0.3%, and BioGlue increased 0.1%. For 2026, management narrowed adjusted constant-currency revenue growth guidance to 8% to 10%, which implies reported revenue of $484 million to $492 million, and narrowed adjusted EBITDA guidance to $93 million to $98 million. Guidance assumes inconsequential U.S. NEXUS revenue in 2026 and about a 1 percentage point FX tailwind for the full year.
Pat Mackin said the quarter reflected continued execution of Artivion’s strategy to build long-term profitable growth around a differentiated product portfolio. He emphasized improving AMDS implant activity, on-track NEXUS launch preparation, strong On-X supply after investment in Austin, and progress in the ARTIZEN trial. His tone was confident and long-term oriented, repeatedly pointing to multiple U.S. aortic growth platforms and a larger innovation pipeline.
Lance Berry highlighted the main financial drivers behind the quarter: higher revenue, but lower EBITDA and margin from Endospan-related costs and gross margin pressure tied to mix plus investments in On-X and NEXUS manufacturing. He cited gross margin of 61.4%, adjusted EBITDA of $22.5 million, and free cash flow of negative $17.6 million, noting that free cash flow was hit by a $13.3 million AMDS PMA milestone payment and about $2 million of Endospan integration expenses. He also noted cash of approximately $48.4 million, debt of $363.8 million net of $6.2 million of unamortized loan origination costs, and net leverage of 3.5x.
Analysts focused on the apparent Q4 growth slowdown, AMDS starter-set bottlenecks, the pace of On-X growth, and whether NEXUS adoption would be gradual or more immediate. Management said the Q4 step-down mostly reflects currency reversing from a tailwind to a headwind and some tissue-processing timing that had outperformed in Q3. On AMDS, they stressed the problem is administrative rather than clinical, with hospitals slow to approve or issue the $100,000 purchase order; on NEXUS, they said surgeon feedback has been excellent and the launch should build through 2027 as training and case volume ramp.
The company still has multiple growth drivers moving at once: AMDS implant volumes are rising, On-X grew 13% with a stronger supply position, and NEXUS is expected to launch in January 2027 with positive surgeon feedback already in hand. Management also highlighted ARTIZEN enrollment progress and a pipeline that they believe expands the U.S. opportunity over time.
Margins were pressured this quarter, with gross margin down to 61.4% and adjusted EBITDA margin down to 18.2% as Artivion absorbed launch, manufacturing, and Endospan-related costs. AMDS remains constrained by slow hospital procurement of the starter set, and management said that barrier may persist for a while even though implant demand is improving. The business also faces a 2027 growth headwind from PerClot, which management said should reduce whatever growth investors were otherwise modeling by 2 percentage points on revenue and 4 percentage points on EBITDA.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.0%
- Shares Outstanding
- 48.79M
- Float Shares
- 46.36M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AORT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Aug 20, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 16, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 9, 25 | Filing → |
| Tina SmithSenate · MN | Buy | Nov 10, 23 | Filing → |
| Tina SmithSenate · MN | Buy | Nov 16, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 14, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 13, 23 | Filing → |
| Tina SmithSenate · MN | Buy | Sep 23, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 292 ETFs
Biggest fund positions in AORT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 10, 26 | GREEN ANDREW M | sell | 11,480 |
| Sep 2, 26 | GREEN ANDREW M | sell | 6,510 |
| Sep 3, 26 | GREEN ANDREW M | sell | 1,493 |
| Aug 19, 26 | Mackin James P | sell | 70,000 |
| Aug 14, 26 | GREEN ANDREW M | sell | 616 |
| Aug 14, 26 | Berry Lance A | sell | 715 |
| Aug 12, 26 | Holloway Jean F | sell | 977 |
| Jun 11, 26 | GREEN ANDREW M | other | 30,000 |
| Jun 11, 26 | GREEN ANDREW M | other | 14,001 |
| Jun 11, 26 | GREEN ANDREW M | sell | 14,001 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AORT coverage
Recent articles, reports, and earnings notes.
No research on AORT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AORT report →Financial Contrast: Zimmer Biomet (NYSE:ZBH) and Artivion (NYSE:AORT)
defenseworld.net · Nov 11
Artivion Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Artivion (AORT) Lags Q3 Earnings Estimates
zacks.com · Nov 5
Artivion Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 5
Artivion to Participate in Upcoming Investor Conferences
prnewswire.com · Oct 28
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
prnewswire.com · Oct 22
Artivion Q2 Earnings Call Highlights
marketbeat.com · Aug 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.